Comparison Guide,Possible dual role for vasoactive intestinal peptide

Vasoactive intestinal peptide (VIP), a fascinating neuropeptide, plays a multifaceted role in various physiological processes. Originally identified as a potent hypotensive and vasodilator peptide, its significance extends far beyond its initial discovery. This in-depth exploration delves into the molecular aspects, immunological functions, and therapeutic potentials of vasoactive intestinal peptide, providing a comprehensive understanding for researchers and healthcare professionals. You can often find detailed research on this topic in PDF format, offering a wealth of scientific data.

First isolated from the porcine small intestine by Said and Mutt, vasoactive intestinal peptide is a 28-amino acid peptide. Its widespread distribution in both the central and peripheral nervous system, as well as in non-neuronal cells like lymphoid cells, underscores its diverse functions. VIP is a member of a family of regulatory peptides and acts as a neurotransmitter and a hormone. The molecular analysis of vasoactive intestinal peptide receptors, specifically VPAC1 and VPAC2, has been crucial in understanding its signaling pathways. These G protein-coupled receptors are quantitatively prominent and mediate many of VIP's effects.

One of the key areas of research is the vasoactive intestinal peptide in the immune system. VIP exerts a wide spectrum of immunological effects. Studies have highlighted its role during intestinal inflammation, as observed in the parasitized ferret. Furthermore, VIP has been shown to inhibit the proliferation of certain cells, suggesting a regulatory role in immune responses. Its presence in nerve fibers within the bone marrow indicates a potential influence on stem cell outcomes.

The possible dual role for vasoactive intestinal peptide as a gastrointestinal hormone and neurotransmitter substance is well-established. VIP is involved in the modulation of gastrointestinal function. For instance, it is implicated in the relaxation of the lower esophageal sphincter (LES), as demonstrated by its effect on the cat isolated lower esophageal sphincter's response to pentagastrin. Intestinal motility is another area where VIP plays a crucial role, with recent research identifying novel neuroimmune mechanisms involving gut microbiota that regulate intestinal function.

Beyond its physiological roles, vasoactive intestinal peptide holds significant therapeutic promise. Potential clinical applications of vasoactive intestinal peptide are vast, with VIP and its analogs showing great potential in the treatment of tumors, diabetes, inflammatory bowel diseases, sepsis, rheumatoid arthritis, and neurodegenerative diseases. Specifically, VIP can stimulate glucose-dependent insulin secretion, particularly by binding to VPAC2 receptors, making it a target for diabetes management. Its anti-inflammatory properties also make it a candidate for treating conditions like inflammatory bowel disease.

Researchers have explored various aspects, including the characterization of vasoactive intestinal peptide receptors on specific tissues, such as rabbit ciliary processes, to understand localized effects. The study of vasoactive intestinal peptide and PHI has also shed light on their influence on hormone secretion, such as the secretion of somatostatin by neurons.

For those seeking detailed scientific literature, the availability of download book PDF options for publications on vasoactive intestinal peptide is invaluable. These resources offer comprehensive data and research findings. The significance of vasoactive intestinal peptide in various biological contexts continues to be a focal point of scientific inquiry, contributing to a deeper understanding of its complex functions and potential applications. The exploration of vasoactive intestinal peptide (VIP) and its receptors remains an active field, promising further advancements in medicine and biology.